Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea3/4TDnetPDF(156KB)
Nxera Pharma to Record Extraordinary Loss on Impairment of Shares of Consolidated Subsidiary (Non-Consolidated)2/13TDnetPDF(114KB)
Variance of Consolidated Results Between the Year Ended 31 December 2025 and the Previous Year2/13TDnetPDF(167KB)
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 20252/13TDnetPDF(191KB)
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals2/12TDnetPDF(109KB)
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea1/19TDnetPDF(152KB)
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa1/13TDnetPDF(109KB)